Silver Oak Securities Incorporated Invests $314,000 in Doximity, Inc. (NASDAQ:DOCS)

Silver Oak Securities Incorporated acquired a new stake in Doximity, Inc. (NASDAQ:DOCS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,880 shares of the company's stock, valued at approximately $314,000.

A number of other large investors also recently made changes to their positions in DOCS. State of Alaska Department of Revenue increased its stake in Doximity by 2.6% during the 4th quarter. State of Alaska Department of Revenue now owns 14,610 shares of the company's stock worth $780,000 after acquiring an additional 370 shares during the period. Bleakley Financial Group LLC raised its holdings in shares of Doximity by 39.7% during the 4th quarter. Bleakley Financial Group LLC now owns 6,839 shares of the company's stock worth $365,000 after buying an additional 1,943 shares in the last quarter. Choreo LLC acquired a new position in shares of Doximity during the 4th quarter worth $256,000. Stratos Wealth Partners LTD. acquired a new position in shares of Doximity during the 4th quarter worth $203,000. Finally, Greenleaf Trust acquired a new position in shares of Doximity during the 4th quarter worth $228,000. Institutional investors own 87.19% of the company's stock.

Wall Street Analyst Weigh In

DOCS has been the subject of a number of research analyst reports. JPMorgan Chase & Co. boosted their price target on Doximity from $30.00 to $48.00 and gave the stock a "neutral" rating in a report on Thursday, November 21st. Bank of America boosted their price target on Doximity from $54.00 to $57.00 and gave the stock a "neutral" rating in a report on Monday, January 6th. Mizuho boosted their price target on Doximity from $55.00 to $65.00 and gave the stock a "neutral" rating in a report on Monday. Piper Sandler upgraded Doximity from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $31.00 to $78.00 in a research report on Friday, February 7th. Finally, Leerink Partners upgraded Doximity from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $60.00 to $90.00 in a research report on Friday, February 7th. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Doximity presently has a consensus rating of "Moderate Buy" and an average target price of $64.22.

Insider Buying and Selling

In related news, Director Timothy S. Cabral sold 20,000 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the transaction, the director now directly owns 6,360 shares of the company's stock, valued at approximately $366,463.20. This represents a 75.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 37.40% of the stock is owned by company insiders.

Doximity Price Performance

Shares of Doximity stock traded up $0.11 on Wednesday, hitting $75.05. 4,154,742 shares of the company's stock traded hands, compared to its average volume of 2,311,001. Doximity, Inc. has a one year low of $22.96 and a one year high of $85.21. The company has a fifty day moving average of $56.61 and a two-hundred day moving average of $46.63. The company has a market capitalization of $14.01 billion, a price-to-earnings ratio of 75.05, a price-to-earnings-growth ratio of 4.61 and a beta of 1.39.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.